The janus face of death receptor signaling during tumor immunoediting

Frontiers in Immunology

Volumn 7, Issue OCT, 2016, Pages

  Reilly, Eimear O' ^a   Tirincsi, Andrea ^a   Logue, Susan E ^a   Szegezdi, Eva ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

Apoptosis; Cancer; FAS (CD95); Immune surveillance; Necroptosis; Pro survival signaling; TNF related apoptosis inducing ligand (TRAIL)

Indexed keywords

CASPASE 3 INHIBITOR; CYTOKINE; DEATH RECEPTOR; DEATH RECEPTOR 4; DEATH RECEPTOR 5; ELONGATION FACTOR 1ALPHA; FAS ANTIGEN; FAS LIGAND; FLICE INHIBITORY PROTEIN; GAMMA INTERFERON; GRANZYME; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; LECTIN RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MATRIX METALLOPROTEINASE; MIXED LINEAGE KINASE; PERFORIN; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN BCL 2; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR DECOY RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VASCULAR ENDOTHELIAL GROWTH INHIBITOR;

ADAPTIVE IMMUNITY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; APOPTOSIS; CANCER THERAPY; CELL DEATH; CUTANEOUS T CELL LYMPHOMA; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; HELPER CELL; HISTONE METHYLATION; HUMAN; IMMUNOEDITING; IMMUNOGENICITY; IMMUNOSURVEILLANCE; INNATE IMMUNITY; NATURAL KILLER CELL; NECROPTOSIS; NEOPLASM; OPSONIZATION; RECOGNITION; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL FACTOR; TRANSFORMED CELL; TUMOR ESCAPE;

EID: 84997553778     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2016.00446     Document Type: Review

References (157)

1. Ehrlich P. über den jetzigen Stand der Karzinomforschung. Ned Tijdschr Geneeskd (1909) 5:273-90.
2. Burnet M. Cancer-a biological approach: III. Viruses associated with neoplastic conditions. IV. practical applications. Br Med J (1957) 1:841-7. doi:10.1136/bmj.1.5023.841.
3. Engel AM, Svane IM, Mouritsen S, Rygaard J, Clausen J, Werdelin O. Methylcholanthrene-induced sarcomas in nude mice have short induction times and relatively low levels of surface MHC class I expression. APMIS (1996) 104:629-39. doi:10.1111/j.1699-0463.1996.tb04923.x.
4. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, et al. Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A (1998) 95:7556-61. doi:10.1073/pnas.95.13.7556.
5. Jeremias I, Herr I, Boehler T, Debatin KM. TRAIL/Apo-2-ligand-induced apoptosis in human T cells. Eur J Immunol (1998) 28:143-52. doi:10.1002/(SICI)1521-4141(199801)28:01<143::AID-IMMU143>3.0.CO;2-3.
6. Zamai L, Ahmad M, Bennett IM, Azzoni L, Alnemri ES, Perussia B. Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J Exp Med (1998) 188:2375-80. doi:10.1084/jem.188.12.2375.
7. Hulpke S, Tampé R. The MHC I loading complex: a multitasking machinery in adaptive immunity. Trends Biochem Sci (2013) 38:412-20. doi:10.1016/j.tibs.2013.06.003.
8. Hoenicke L, Zender L. Immune surveillance of senescent cells-biological significance in cancer-and non-cancer pathologies. Carcinogenesis (2012) 33:1123-6. doi:10.1093/carcin/bgs124.
9. Chan CJ, Smyth MJ, Martinet L. Molecular mechanisms of natural killer cell activation in response to cellular stress. Cell Death Differ (2014) 21:5-14. doi:10.1038/cdd.2013.26.
10. Marcus A, Gowen BG, Thompson TW, Iannello A, Ardolino M, Deng W, et al. Recognition of tumors by the innate immune system and natural killer cells. Adv Immunol (2014) 122:91-128. doi:10.1016/B978-0-12-800267-4.00003-1.
11. Karsunky H, Inlay MA, Serwold T, Bhattacharya D, Weissman IL. Flk2+ common lymphoid progenitors possess equivalent differentiation potential for the B and T lineages. Blood (2008) 111:5562-70. doi:10.1182/blood-2007-11-126219.
12. Yu J, Freud AG, Caligiuri MA. Location and cellular stages of natural killer cell development. Trends Immunol (2013) 34:573-82. doi:10.1016/j.it.2013.07.005.
13. Long EO, Rajagopalan S. Stress signals activate natural killer cells. J Exp Med (2002) 196:1399-402. doi:10.1084/jem.20021747.
14. Pegram HJ, Andrews DM, Smyth MJ, Darcy PK, Kershaw MH. Activating and inhibitory receptors of natural killer cells. Immunol Cell Biol (2011) 89:216-24. doi:10.1038/icb.2010.78.
15. Jaeger BN, Vivier E. Natural killer cell tolerance: control by self or self-control? Cold Spring Harb Perspect Biol (2012) 4:a007229. doi:10.1101/cshperspect.a007229.
16. Campbell KS, Hasegawa J. Natural killer cell biology: an update and future directions. J Allergy ClinImmunol (2013) 132:536-44. doi:10.1016/j.jaci.2013.07.006.
17. Long EO, Barber DF, Burshtyn DN, Faure M, Peterson M, Rajagopalan S, et al. Inhibition of natural killer cell activation signals by killer cell immunoglobulin-like receptors (CD158). Immunol Rev (2001) 181:223-33. doi:10.1034/j.1600-065X.2001.1810119.x.
18. Borrego F, Masilamani M, Kabat J, Sanni TB, Coligan JE. The cell biology of the human natural killer cell CD94/NKG2A inhibitory receptor. Mol Immunol (2005) 42:485-8. doi:10.1016/j.molimm.2004.07.031.
19. Haworth KB, Leddon JL, Chen CY, Horwitz EM, Mackall CL, Cripe TP. Going back to class I: MHC and immunotherapies for childhood cancer. Pediatr Blood Cancer (2015) 62:571-6. doi:10.1002/pbc.25359.
20. Stephens HA. MICA and MICB genes: can the enigma of their polymorphism be resolved? Trends Immunol (2001) 22:378-85. doi:10.1016/S1471-4906(01)01960-3.
21. Waldhauer I, Steinle A. NK cells and cancer immunosurveillance. Oncogene (2008) 27:5932-43. doi:10.1038/onc.2008.267.
22. Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer (2012) 12:860-75. doi:10.1038/nrc3380.
23. Weiss-Steider B, Soto-Cruz I, Martinez-Campos CA, Mendoza-Rincon JF. Expression of MICA, MICB and NKG2D in human leukemic myelomonocytic and cervical cancer cells. J Exp Clin Cancer Res (2011) 30:37-37. doi:10.1186/1756-9966-30-37.
24. Seidel UJE, Schlegel P, Lang P. Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies. Front Immunol (2013) 4:76. doi:10.3389/fimmu.2013.00076.
25. Poli A, Michel T, Thérésine M, Andrès E, Hentges F, Zimmer J. CD56(bright) natural killer (NK) cells: an important NK cell subset. Immunology (2009) 126:458-65. doi:10.1111/j.1365-2567.2008.03027.x.
26. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (2006) 314:126-9. doi:10.1126/science.1129003.
27. Broere F, Apasov SG, Sitkovsky MV, Van Eden W. A2 T cell subsets and T cell-mediated immunity. In: Nijkamp FP, Parnham MJ, editors. Principles of Immunopharmacology. Basel: Springer (2011). p. 15-27.
28. Andersen MH, Schrama D, Thor Straten P, Becker JC. Cytotoxic T cells. J Invest Dermatol (2006) 126:32-41. doi:10.1038/sj.jid.5700001.
29. Haabeth OAW, Tveita AA, Fauskanger M, Schjesvold F, Lorvik KB, Hofgaard PO, et al. How do CD4(+) T cells detect and eliminate tumor cells that either lack or express MHC class II molecules? Front Immunol (2014) 5:174. doi:10.3389/fimmu.2014.00174.
30. Zhang S, Zhang H, Zhao J. The role of CD4 T cell help for CD8 CTL activation. Biochem Biophys Res Commun (2009) 384:405-8. doi:10.1016/j.bbrc.2009.04.134.
31. Luckheeram RV, Zhou R, Verma AD, Xia B. CD4+T cells: differentiation and functions. Clin Dev Immunol (2012) 2012:12. doi:10.1155/2012/925135.
32. Fehniger TA, Shah MH, Turner MJ, Vandeusen JB, Whitman SP, Cooper MA, et al. Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. J Immunol (1999) 162:4511-20.
33. Ritz J. NK cell cytokine secretion regulated by SHIP1. Blood (2005) 105:3003-3003. doi:10.1182/blood-2005-02-0445.
34. Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T Cell populations. Annu Rev Immunol (2010) 28:445-89. doi:10.1146/annurev-immunol-030409-101212.
35. Walczak H. Death receptor-ligand systems in cancer, cell death, and inflammation. Cold Spring Harb Perspect Biol (2013) 5:a008698. doi:10.1101/cshperspect.a008698.
36. Mocarski ES, Kaiser WJ, Livingston-RosanoffD, Upton JW, Daley-Bauer LP. True grit: programmed necrosis in antiviral host defense, inflammation, and immunogenicity. J Immunol (2014) 192:2019-26. doi:10.4049/jimmunol.1302426.
37. Guicciardi ME, Gores GJ. Life and death by death receptors. FASEB J (2009) 23:1625-37. doi:10.1096/fj.08-111005.
38. Naude PJ, Den Boer JA, Luiten PG, Eisel UL. Tumor necrosis factor receptor cross-talk. FEBS J (2011) 278:888-98. doi:10.1111/j.1742-4658.2011.08017.x.
39. Chan FK-M, Chun HJ, Zheng L, Siegel RM, Bui KL, Lenardo MJ. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science (2000) 288:2351-4. doi:10.1126/science.288.5475.2351.
40. Siegel RM, Frederiksen JK, Zacharias DA, Chan FK, Johnson M, Lynch D, et al. Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. Science (2000) 288:2354-7. doi:10.1126/science.288.5475.2354.
41. Sessler T, Healy S, Samali A, Szegezdi E. Structural determinants of DISC function: new insights into death receptor-mediated apoptosis signalling. Pharmacol Ther (2013) 140:186-99. doi:10.1016/j.pharmthera.2013.06.009.
42. Riley JS, Malik A, Holohan C, Longley DB. DED or alive: assembly and regulation of the death effector domain complexes. Cell Death Dis (2015) 6:e1866. doi:10.1038/cddis.2015.213.
43. Scaffidi C, Schmitz I, Krammer PH, Peter ME. The role of c-FLIP in modulation of CD95-induced apoptosis. J Biol Chem (1999) 274:1541-8. doi:10.1074/jbc.274.3.1541.
44. Schug ZT, Gonzalvez F, Houtkooper RH, Vaz FM, Gottlieb E. BID is cleaved by caspase-8 within a native complex on the mitochondrial membrane. Cell Death Differ (2011) 18:538-48. doi:10.1038/cdd.2010.135.
45. Dewson G, Kluck RM. Mechanisms by which Bak and Bax permeabilise mitochondria during apoptosis. J Cell Sci (2009) 122:2801-8. doi:10.1242/jcs.038166.
46. Westphal D, Kluck RM, Dewson G. Building blocks of the apoptotic pore: how Bax and Bak are activated and oligomerize during apoptosis. Cell Death Differ (2014) 21:196-205. doi:10.1038/cdd.2013.139.
47. Riedl SJ, Li W, Chao Y, Schwarzenbacher R, Shi Y. Structure of the apoptotic protease-activating factor 1 bound to ADP. Nature (2005) 434:926-33. doi:10.1038/nature03465.
48. Bratton SB, Cohen GM. Apoptotic death sensor: an organelle's alter ego? Trends Pharmacol Sci (2001) 22:306-15. doi:10.1016/S0165-6147(00)01718-1.
49. Kim M, Hernandez L, Annunziata CM. Caspase 8 expression may determine the survival of women with ovarian cancer. Cell Death Dis (2016) 7:e2045. doi:10.1038/cddis.2015.398.
50. Wang H, Sun L, Su L, Rizo J, Liu L, Wang L-F, et al. Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption upon phosphorylation by RIP3. Mol Cell (2014) 54:133-46. doi:10.1016/j.molcel.2014.03.003.
51. Dondelinger Y, Declercq W, Montessuit S, Roelandt R, Goncalves A, Bruggeman I, et al. MLKL compromises plasma membrane integrity by binding to phosphatidylinositol phosphates. Cell Rep (2014) 7:971-81. doi:10.1016/j.celrep.2014.04.026.
52. Xia B, Fang S, Chen X, Hu H, Chen P, Wang H, et al. MLKL forms cation channels. Cell Res (2016) 26:517-28. doi:10.1038/cr.2016.26.
53. Cai Z, Jitkaew S, Zhao J, Chiang H-C, Choksi S, Liu J, et al. Plasma membrane translocation of trimerized MLKL protein is required for TNF-induced necroptosis. Nat Cell Biol (2014) 16:55-65. doi:10.1038/ncb2883.
54. Lu JV, Chen HC, Walsh CM. Necroptotic signaling in adaptive and innate immunity. Semin Cell Dev Biol (2014) 35:33-9. doi:10.1016/j.semcdb.2014.07.003.
55. Zhang L, Blackwell K, Workman LM, Chen S, Pope MR, Janz S, et al. RIP1 cleavage in the kinase domain regulates TRAIL-induced NF-kappaB activation and lymphoma survival. Mol Cell Biol (2015) 35:3324-38. doi:10.1128/MCB.00692-15.
56. Cullen SP, Martin SJ. Mechanisms of granule-dependent killing. Cell Death Differ (2008) 15:251-62. doi:10.1038/sj.cdd.4402244.
57. Sutton VR, Davis JE, Cancilla M, Johnstone RW, Ruefli AA, Sedelies K, et al. Initiation of apoptosis by granzyme B requires direct cleavage of bid, but not direct granzyme B-mediated caspase activation. J Exp Med (2000) 192:1403-14. doi:10.1084/jem.192.10.1403.
58. Cullen SP, Adrain C, Lüthi AU, Duriez PJ, Martin SJ. Human and murine granzyme B exhibit divergent substrate preferences. J Cell Biol (2007) 176:435-44. doi:10.1083/jcb.200612025.
59. Fan Z, Beresford PJ, Oh DY, Zhang D, Lieberman J. Tumor suppressor NM23-H1 is a granzyme A-activated DNase during CTL-mediated apoptosis, and the nucleosome assembly protein SET is its inhibitor. Cell (2003) 112:659-72. doi:10.1016/S0092-8674(03)00150-8.
60. Lieberman J. Granzyme A activates another way to die. Immunol Rev (2010) 235:93-104. doi:10.1111/j.0105-2896.2010.00902.x.
61. Zhu P, Martinvalet D, Chowdhury D, Zhang D, Schlesinger A, Lieberman J. The cytotoxic T lymphocyte protease granzyme A cleaves and inactivates poly(adenosine 5'-diphosphate-ribose) polymerase-1. Blood (2009) 114:1205-16. doi:10.1182/blood-2008-12-195768.
62. Beresford PJ, Zhang D, Oh DY, Fan Z, Greer EL, Russo ML, et al. Granzyme A activates an endoplasmic reticulum-associated caspase-independent nuclease to induce single-stranded DNA nicks. J Biol Chem (2001) 276:43285-93. doi:10.1074/jbc. M108137200.
63. Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape. Curr Opin Immunol (2014) 27:16-25. doi:10.1016/j.coi.2014.01.004.
64. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol (2006) 6:836-48. doi:10.1038/nri1961.
65. Teng MW, Galon J, Fridman WH, Smyth MJ. From mice to humans: developments in cancer immunoediting. J Clin Invest (2015) 125:3338-46. doi:10.1172/JCI80004.
66. van Dijk M, Halpin-Mccormick A, Sessler T, Samali A, Szegezdi E. Resistance to TRAIL in non-transformed cells is due to multiple redundant pathways. Cell Death Dis (2013) 4:e702. doi:10.1038/cddis.2013.214.
67. Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B, et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med (2001) 7:383-5. doi:10.1038/86397.
68. Lu X, Arbiser JL, West J, Hoedt-Miller M, Sheridan A, Govindarajan B, et al. Tumor necrosis factor-related apoptosis-inducing ligand can induce apoptosis in subsets of premalignant cells. Am J Pathol (2004) 165:1613-20. doi:10.1016/S0002-9440(10)63418-9.
69. Nesterov A, Nikrad M, Johnson T, Kraft AS. Oncogenic Ras sensitizes normal human cells to tumor necrosis factor-alpha-related apoptosis-inducing ligand-induced apoptosis. Cancer Res (2004) 64:3922-7. doi:10.1158/0008-5472.CAN-03-2219.
70. Hague A, Hicks DJ, Hasan F, Smartt H, Cohen GM, Paraskeva C, et al. Increased sensitivity to TRAIL-induced apoptosis occurs during the adenoma to carcinoma transition of colorectal carcinogenesis. Br J Cancer (2005) 92:736-42. doi:10.1038/sj.bjc.6602387.
71. White-Gilbertson S, Rubinchik S, Voelkel-Johnson C. Transformation, translation and TRAIL: an unexpected intersection. Cytokine Growth Factor Rev (2008) 19:167-72. doi:10.1016/j.cytogfr.2008.01.007.
72. Yang H, Chen X, Wang X, Li Y, Chen S, Qian X, et al. Inhibition of PP2A activity confers a TRAIL-sensitive phenotype during malignant transformation. Mol Cancer Res (2014) 12:217-27. doi:10.1158/1541-7786.MCR-13-0441.
73. Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ, Smyth MJ. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol (2002) 168:1356-61. doi:10.4049/jimmunol.168.3.1356.
74. Takeda K, Smyth MJ, Cretney E, Hayakawa Y, Kayagaki N, Yagita H, et al. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med (2002) 195:161-9. doi:10.1084/jem.20011171.
75. Yip KW, Reed JC. Bcl-2 family proteins and cancer. Oncogene (2008) 27:6398-406. doi:10.1038/onc.2008.307.
76. Obexer P, Ausserlechner MJ. X-linked inhibitor of apoptosis protein-a critical death resistance regulator and therapeutic target for personalized cancer therapy. Front Oncol (2014) 4:197. doi:10.3389/fonc.2014.00197.
77. Kiaei M, Kipiani K, Calingasan NY, Wille E, Chen J, Heissig B, et al. Matrix metalloproteinase-9 regulates TNF-alpha and FasL expression in neuronal, glial cells and its absence extends life in a transgenic mouse model of amyotrophic lateral sclerosis. Exp Neurol (2007) 205:74-81. doi:10.1016/j.expneurol.2007.01.036.
78. Schulte M, Reiss K, Lettau M, Maretzky T, Ludwig A, Hartmann D, et al. ADAM10 regulates FasL cell surface expression and modulates FasL-induced cytotoxicity and activation-induced cell death. Cell Death Differ (2007) 14:1040-9. doi:10.1038/sj.cdd.4402101.
79. Ebsen H, Lettau M, Kabelitz D, Janssen O. Subcellular localization and activation of ADAM proteases in the context of FasL shedding in T lymphocytes. Mol Immunol (2015) 65:416-28. doi:10.1016/j.molimm.2015.02.008.
80. Schneider P, Holler N, Bodmer JL, Hahne M, Frei K, Fontana A, et al. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med (1998) 187:1205-13. doi:10.1084/jem.187.8.1205.
81. Suda T, Hashimoto H, Tanaka M, Ochi T, Nagata S. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble fas ligand blocks the killing. J Exp Med (1997) 186:2045-50. doi:10.1084/jem.186.12.2045.
82. O' Reilly LA, Tai L, Lee L, Kruse EA, Grabow S, Fairlie WD, et al. Membrane-bound Fas ligand only is essential for Fas-induced apoptosis. Nature (2009) 461:659-63. doi:10.1038/nature08402.
83. Petak I, Danam RP, Tillman DM, Vernes R, Howell SR, Berczi L, et al. Hypermethylation of the gene promoter and enhancer region can regulate Fas expression and sensitivity in colon carcinoma. Cell Death Differ (2003) 10:211-7. doi:10.1038/sj.cdd.4401132.
84. Wu J, Nihal M, Siddiqui J, Vonderheid EC, Wood GS. Low FAS/CD95 expression by CTCL correlates with reduced sensitivity to apoptosis that can be restored by FAS upregulation. J Invest Dermatol (2009) 129:1165-73. doi:10.1038/jid.2008.309.
85. Lemke J, Von Karstedt S, Zinngrebe J, Walczak H. Getting TRAIL back on track for cancer therapy. Cell Death Differ (2014) 21:1350-64. doi:10.1038/cdd.2014.81.
86. Wang W, Qi X, Wu M. Effect of DR4 promoter methylation on the TRAIL-induced apoptosis in lung squamous carcinoma cell. Oncol Rep (2015) 34:2115-25. doi:10.3892/or.2015.4170.
87. Kriegl L, Jung A, Engel J, Jackstadt R, Gerbes AL, Gallmeier E, et al. Expression, cellular distribution, and prognostic relevance of TRAIL receptors in hepatocellular carcinoma. Clin Cancer Res (2010) 16:5529-38. doi:10.1158/1078-0432.CCR-09-3403.
88. Paschall AV, Yang D, Lu C, Choi JH, Li X, Liu F, et al. H3K9 trimethylation silences fas expression to confer colon carcinoma immune escape and 5-fluorouracil chemoresistance. J Immunol (2015) 195:1868-82. doi:10.4049/jimmunol.1402243.
89. Peli J, Schröter M, Rudaz C, Hahne M, Meyer C, Reichmann E, et al. Oncogenic Ras inhibits Fas ligand-mediated apoptosis by downregulating the expression of Fas. EMBO J (1999) 18:1824-31. doi:10.1093/emboj/18.7.1824.
90. Gazin C, Wajapeyee N, Gobeil S, Virbasius C-M, Green MR. An elaborate pathway required for Ras-mediated epigenetic silencing. Nature (2007) 449:1073-7. doi:10.1038/nature06251.
91. Yang Q, Kiernan CM, Tian Y, Salwen HR, Chlenski A, Brumback BA, et al. Methylation of CASP8, DCR2, and HIN-1 in neuroblastoma is associated with poor outcome. Clin Cancer Res (2007) 13:3191-7. doi:10.1158/1078-0432.CCR-06-2846.
92. Pingoud-Meier C, Lang D, Janss AJ, Rorke LB, Phillips PC, Shalaby T, et al. Loss of caspase-8 protein expression correlates with unfavorable survival outcome in childhood medulloblastoma. Clin Cancer Res (2003) 9:6401-9.
93. Shivapurkar N, Toyooka S, Eby MT, Huang CX, Sathyanarayana UG, Cunningham HT, et al. Differential inactivation of caspase-8 in lung cancers. Cancer Biol Ther (2002) 1:65-9. doi:10.4161/cbt.1.1.45.
94. Johnson BE, Ihde DC, Makuch RW, Gazdar AF, Carney DN, Oie H, et al. myc family oncogene amplification in tumor cell lines established from small cell lung cancer patients and its relationship to clinical status and course. J Clin Invest (1987) 79:1629-34. doi:10.1172/JCI112999.
95. Johnson BE, Brennan JF, Ihde DC, Gazdar AF. myc family DNA amplification in tumors and tumor cell lines from patients with small-cell lung cancer. J Natl Cancer Inst Monogr (1992) (13):39-43.
96. Yokota J, Wada M, Yoshida T, Noguchi M, Terasaki T, Shimosato Y, et al. Heterogeneity of lung cancer cells with respect to the amplification and rearrangement of myc family oncogenes. Oncogene (1988) 2:607-11.
97. Almasan A, Ashkenazi A. Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev (2003) 14:337-48. doi:10.1016/S1359-6101(03)00029-7.
98. Chan FK-M. Three is better than one: pre-ligand receptor assembly in the regulation of TNF receptor signaling. Cytokine (2007) 37:101-7. doi:10.1016/j.cyto.2007.03.005.
99. Riccioni R, Pasquini L, Mariani G, Saulle E, Rossini A, Diverio D, et al. TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL. Haematologica (2005) 90:612-24.
100. Anees M, Horak P, El-Gazzar A, Susani M, Heinze G, Perco P, et al. Recurrence-free survival in prostate cancer is related to increased stromal TRAIL expression. Cancer (2011) 117:1172-82. doi:10.1002/cncr.25504.
101. O' Leary L, Van Der Sloot AM, Reis CR, Deegan S, Ryan AE, Dhami SPS, et al. Decoy receptors block TRAIL sensitivity at a supracellular level: the role of stromal cells in controlling tumour TRAIL sensitivity. Oncogene (2016) 35:1261-70. doi:10.1038/onc.2015.180.
102. Finnberg N, Klein-Szanto AJP, El-Deiry WS. TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis. J Clin Invest (2008) 118:111-23. doi:10.1172/JCI29900.
103. Vitovski S, Phillips JS, Sayers J, Croucher PI. Investigating the interaction between osteoprotegerin and receptor activator of NF-κB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways. J Biol Chem (2007) 282:31601-9. doi:10.1074/jbc. M706078200.
104. Zauli G, Melloni E, Capitani S, Secchiero P. Role of full-length osteoprotegerin in tumor cell biology. Cell Mol Life Sci (2009) 66:841-51. doi:10.1007/s00018-008-8536-x.
105. Toda M, Kawamoto T, Ueha T, Kishimoto K, Hara H, Fukase N, et al. 'Decoy' and 'non-decoy' functions of DcR3 promote malignant potential in human malignant fibrous histiocytoma cells. Int J Oncol (2013) 43:703-12. doi:10.3892/ijo.2013.1999.
106. Dougall WC, Holen I, Gonzalez Suarez E. Targeting RANKL in metastasis. Bonekey Rep (2014) 3:519. doi:10.1038/bonekey.2014.14.
107. Yang CR, Hsieh SL, Teng CM, Ho FM, Su WL, Lin WW. Soluble decoy receptor 3 induces angiogenesis by neutralization of TL1A, a cytokine belonging to tumor necrosis factor superfamily and exhibiting angiostatic action. Cancer Res (2004) 64:1122-9. doi:10.1158/0008-5472.CAN-03-0609.
108. Lin W-W, Hsieh S-L. Decoy receptor 3: a pleiotropic immunomodulator and biomarker for inflammatory diseases, autoimmune diseases and cancer. Biochem Pharmacol (2011) 81:838-47. doi:10.1016/j.bcp.2011.01.011.
109. Tauzin S, Debure L, Moreau J-F, Legembre P. CD95-mediated cell signaling in cancer: mutations and post-translational modulations. Cell Mol Life Sci (2012) 69:1261-77. doi:10.1007/s00018-011-0866-4.
110. Peter ME, Legembre P, Barnhart BC. Does CD95 have tumor promoting activities? Biochim Biophys Acta (2005) 1755:25-36. doi:10.1016/j.bbcan.2005.01.001.
111. Lee SH, Shin MS, Kim HS, Lee HK, Park WS, Kim SY, et al. Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers. Cancer Res (1999) 59:5683-6.
112. Lee SH, Shin MS, Kim HS, Lee HK, Park WS, Kim SY, et al. Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin's lymphoma. Oncogene (2001) 20:399-403. doi:10.1038/sj.onc.1204103.
113. Shin MS, Kim HS, Lee SH, Park WS, Kim SY, Park JY, et al. Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers. Cancer Res (2001) 61:4942-6.
114. Pai SI, Wu GS, özören N, Wu L, Jen J, Sidransky D, et al. Rare loss-of-function mutation of a death receptor gene in head and neck cancer. Cancer Res (1998) 58:3513-8.
115. Yang H, Song Y. Structural insight for roles of DR5 death domain mutations on oligomerization of DR5 death domain-FADD complex in the death-inducing signaling complex formation: a computational study. J Mol Model (2016) 22:1-12. doi:10.1007/s00894-016-2941-0.
116. Park WS, Lee JH, Shin MS, Park JY, Kim HS, Kim YS, et al. Inactivating mutations of KILLER/DR5 gene in gastric cancers. Gastroenterology (2001) 121:1219-25. doi:10.1053/gast.2001.28663.
117. Jeng Y-M, Hsu H-C. Mutation of the DR5/TRAIL receptor 2 gene is infrequent in hepatocellular carcinoma. Cancer Lett (2002) 181:205-8. doi:10.1016/S0304-3835(02)00051-4.
118. Adams J, Cuthbert-Heavens D, Bass S, Knowles MA. Infrequent mutation of TRAIL receptor 2 (TRAIL-R2/DR5) in transitional cell carcinoma of the bladder with 8p21 loss of heterozygosity. Cancer Lett (2005) 220:137-44. doi:10.1016/j.canlet.2004.06.052.
119. Lens SM, Kataoka T, Fortner KA, Tinel A, Ferrero I, Macdonald RH, et al. The caspase 8 inhibitor c-FLIP(L) modulates T-cell receptor-induced proliferation but not activation-induced cell death of lymphocytes. Mol Cell Biol (2002) 22:5419-33. doi:10.1128/MCB.22.15.5419-5433.2002.
120. Tian F, Lu JJ, Wang L, Li L, Yang J, Li Y, et al. Expression of c-FLIP in malignant melanoma, and its relationship with the clinicopathological features of the disease. Clin Exp Dermatol (2012) 37:259-65. doi:10.1111/j.1365-2230.2011.04238.x.
121. McCourt C, Maxwell P, Mazzucchelli R, Montironi R, Scarpelli M, Salto-Tellez M, et al. Elevation of c-FLIP in castrate-resistant prostate cancer antagonizes therapeutic response to androgen receptor-targeted therapy. Clin Cancer Res (2012) 18:3822-33. doi:10.1158/1078-0432.CCR-11-3277.
122. Ewald F, Ueffing N, Brockmann L, Hader C, Telieps T, Schuster M, et al. The role of c-FLIP splice variants in urothelial tumours. Cell Death Dis (2011) 2:e245. doi:10.1038/cddis.2011.131.
123. Safa AR. c-FLIP, a master anti-apoptotic regulator. Exp Oncol (2012) 34:176-84.
124. Salvesen GS, Walsh CM. Functions of caspase 8: the identified and the mysterious. Semin Immunol (2014) 26:246-52. doi:10.1016/j.smim.2014.03.005.
125. Safa AR. Roles of c-FLIP in apoptosis, necroptosis, and autophagy. J Carcinog Mutagen (2013) (Suppl 6):3. doi:10.4172/2157-2518.S6-003.
126. Kataoka T, Tschopp J. N-terminal fragment of c-FLIP(L) processed by caspase 8 specifically interacts with TRAF2 and induces activation of the NF-κB signaling pathway. Mol Cell Biol (2004) 24:2627-36. doi:10.1128/MCB.24.7.2627-2636.2004.
127. Berghe TV, Linkermann A, Jouan-Lanhouet S, Walczak H, Vandenabeele P. Regulated necrosis: the expanding network of non-apoptotic cell death pathways. Nat Rev Mol Cell Biol (2014) 15:135-47. doi:10.1038/nrm3737.
128. Altieri DC. Survivin and IAP proteins in cell death mechanisms. Biochem J (2010) 430:199-205. doi:10.1042/BJ20100814.
129. Labbé K, McIntire CR, Doiron K, Leblanc PM, Saleh M. Cellular inhibitors of apoptosis proteins cIAP1 and cIAP2 are required for efficient caspase-1 activation by the inflammasome. Immunity (2011) 35:897-907. doi:10.1016/j.immuni.2011.10.016.
130. Holcik M, Korneluk RG. XIAP, the guardian angel. Nat Rev Mol Cell Biol (2001) 2:550-6. doi:10.1038/35080103.
131. Choi JS, Park BC, Chi SW, Bae K-H, Kim S, Cho S, et al. HAX1 regulates E3 ubiquitin ligase activity of cIAPs by promoting their dimerization. Oncotarget (2014) 5:10084-99. doi:10.18632/oncotarget.2459.
132. Wertz IE, Dixit VM. Signaling to NF-κB: regulation by ubiquitination. Cold Spring Harb Perspect Biol (2010) 2:a003350. doi:10.1101/cshperspect.a003350.
133. Mahalingam D, Szegezdi E, Keane M, De Jong S, Samali A. TRAIL receptor signalling and modulation: are we on the right TRAIL? Cancer Treat Rev (2009) 35:280-8. doi:10.1016/j.ctrv.2008.11.006.
134. Tait SWG, Ichim G, Green DR. Die another way-non-apoptotic mechanisms of cell death. J Cell Sci (2014) 127:2135-44. doi:10.1242/jcs.093575.
135. Freimuth J, Bangen JM, Lambertz D, Hu W, Nevzorova YA, Sonntag R, et al. Loss of caspase-8 in hepatocytes accelerates the onset of liver regeneration in mice through premature nuclear factor kappa B activation. Hepatology (2013) 58:1779-89. doi:10.1002/hep.26538.
136. Dondelinger Y, Darding M, Bertrand MJM, Walczak H. Poly-ubiquitination in TNFR1-mediated necroptosis. Cell Mol Life Sci (2016) 73:2165-76. doi:10.1007/s00018-016-2191-4.
137. von Karstedt S, Conti A, Nobis M, Montinaro A, Hartwig T, Lemke J, et al. Cancer cell-autonomous TRAIL-R signaling promotes KRAS-driven cancer progression, invasion, and metastasis. Cancer Cell (2015) 27:561-73. doi:10.1016/j.ccell.2015.02.014.
138. Gadea G, Sanz-Moreno V, Self A, Godi A, Marshall CJ. DOCK10-mediated Cdc42 activation is necessary for amoeboid invasion of melanoma cells. Curr Biol (2008) 18:1456-65. doi:10.1016/j.cub.2008.08.053.
139. Hoogwater FJ, Nijkamp MW, Smakman N, Steller EJ, Emmink BL, Westendorp BF, et al. Oncogenic K-Ras turns death receptors into metastasis-promoting receptors in human and mouse colorectal cancer cells. Gastroenterology (2010) 138:2357-67. doi:10.1053/j.gastro.2010.02.046.
140. Azijli K, Yuvaraj S, Peppelenbosch MP, Wurdinger T, Dekker H, Joore J, et al. Kinome profiling of non-canonical TRAIL signaling reveals RIP1-Src-STAT3-dependent invasion in resistant non-small cell lung cancer cells. J Cell Sci (2012) 125:4651-61. doi:10.1242/jcs.109587.
141. Spierings DC, De Vries EG, Timens W, Groen HJ, Boezen HM, De Jong S. Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors. Clin Cancer Res (2003) 9:3397-405.
142. Tauzin S, Chaigne-Delalande B, Selva E, Khadra N, Daburon S, Contin-Bordes C, et al. The naturally processed CD95L elicits a c-Yes/calcium/PI3K-driven cell migration pathway. PLoS Biol (2011) 9:e1001090. doi:10.1371/journal.pbio.1001090.
143. Kleber S, Sancho-Martinez I, Wiestler B, Beisel A, Gieffers C, Hill O, et al. Yes and PI3K bind CD95 to signal invasion of glioblastoma. Cancer Cell (2008) 13:235-48. doi:10.1016/j.ccr.2008.02.003.
144. Khadra N, Bresson-Bepoldin L, Penna A, Chaigne-Delalande B, Segui B, Levade T, et al. CD95 triggers Orai1-mediated localized Ca2+ entry, regulates recruitment of protein kinase C (PKC) beta2, and prevents death-inducing signaling complex formation. Proc Natl Acad Sci U S A (2011) 108:19072-7. doi:10.1073/pnas.1116946108.
145. Monet M, Poet M, Tauzin S, Fouque A, Cophignon A, Lagadic-Gossmann D, et al. The cleaved FAS ligand activates the Na(+)/H(+) exchanger NHE1 through Akt/ROCK1 to stimulate cell motility. Sci Rep (2016) 6:28008. doi:10.1038/srep28008.
146. Ehrenschwender M, Siegmund D, Wicovsky A, Kracht M, Dittrich-Breiholz O, Spindler V, et al. Mutant PIK3CA licenses TRAIL and CD95L to induce non-apoptotic caspase-8-mediated ROCK activation. Cell Death Differ (2010) 17:1435-47. doi:10.1038/cdd.2010.36.
147. Creagan ET, Kovach JS, Moertel CG, Frytak S, Kvols LK. A phase I clinical trial of recombinant human tumor necrosis factor. Cancer (1988) 62:2467-71. doi:10.1002/1097-0142(19881215)62:12<2467::AID-CNCR2820621202>3.0.CO;2-5.
148. Galle PR, Hofmann WJ, Walczak H, Schaller H, Otto G, Stremmel W, et al. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med (1995) 182:1223-30. doi:10.1084/jem.182.5.1223.
149. Jodo S, Kung JT, Xiao S, Chan DV, Kobayashi S, Tateno M, et al. Anti-CD95-induced lethality requires radioresistant FcγRII+ cells: a novel mechanism for fulminant hepatic failure. J Biol Chem (2003) 278:7553-7. doi:10.1074/jbc. M211229200.
150. Bremer E. Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy. ISRN Oncol (2013) 2013:371854. doi:10.1155/2013/371854.
151. Ashkenazi A. Targeting the extrinsic apoptotic pathway in cancer: lessons learned and future directions. J Clin Invest (2015) 125:487-9. doi:10.1172/JCI80420.
152. van der Sloot AM, Tur V, Szegezdi E, Mullally MM, Cool RH, Samali A, et al. Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor. Proc Natl Acad Sci U S A (2006) 103:8634-9. doi:10.1073/pnas.0510187103.
153. den Hollander MW, Gietema JA, De Jong S, Walenkamp AM, Reyners AK, Oldenhuis CN, et al. Translating TRAIL-receptor targeting agents to the clinic. Cancer Lett (2013) 332:194-201. doi:10.1016/j.canlet.2012.04.007.
154. de Bruyn M, Wei Y, Wiersma VR, Samplonius DF, Klip HG, Van Der Zee AG, et al. Cell surface delivery of TRAIL strongly augments the tumoricidal activity of T cells. Clin Cancer Res (2011) 17:5626-37. doi:10.1158/1078-0432.CCR-11-0303.
155. Campoli MR, Chang CC, Kageshita T, Wang X, Mccarthy JB, Ferrone S. Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance. Crit Rev Immunol (2004) 24:267-96. doi:10.1615/CritRevImmunol.v24.i4.40.
156. He Y, Hendriks D, Van Ginkel R, Samplonius D, Bremer E, Helfrich W. Melanoma-directed activation of apoptosis using a bispecific antibody directed at MCSP and TRAIL receptor-2/death receptor-5. J Invest Dermatol (2016) 136:541-4. doi:10.1016/j.jid.2015.11.009.
157. Corazza N, Jakob S, Schaer C, Frese S, Keogh A, Stroka D, et al. TRAIL receptor-mediated JNK activation and Bim phosphorylation critically regulate Fas-mediated liver damage and lethality. J Clin Invest (2006) 116:2493-9. doi:10.1172/JCI27726.